Vir Biotechnology, Inc. Restructuring Costs and Asset Impairment Charges
Vir Biotechnology, Inc. (VIR) reported Restructuring Costs and Asset Impairment Charges of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2026-08-05
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for the quarter ending 2026-06-30 was $0.00.
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for the quarter ending 2026-03-31 was $0.00.
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for the quarter ending 2025-12-31 was $0.00.
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for fiscal 2025 was -$182.00K, a 100.52% decline from fiscal 2024.
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for fiscal 2024 was $34.99M, a 158.09% increase from fiscal 2023.
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for fiscal 2023 was $13.56M.
- Vir Biotechnology, Inc. restructuring costs and asset impairment charges for fiscal 2022 was $0.00.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | -$172.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | -$172.00K derived: sum of 3 quarters · filed 2026-08-05 | -$182.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | -$172.00K derived: sum of 2 quarters · filed 2026-08-05 | -$182.00K 10-Q · filed 2025-11-05 | -$4.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$172.00K 10-Q · filed 2026-08-05 | -$182.00K 10-Q · filed 2026-08-05 | -$4.13M derived: sum of 3 quarters · filed 2026-08-05 | $8.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$10.00K 10-Q · filed 2026-05-07 | -$3.95M derived: sum of 2 quarters · filed 2026-05-07 | $8.76M derived: sum of 3 quarters · filed 2026-05-07 | $35.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.77M derived: sum of 2 quarters · filed 2026-02-23 | $35.04M derived: sum of 3 quarters · filed 2026-02-23 | $34.99M 10-K · filed 2026-02-23 |
| 2024-09-30 | $12.71M 10-Q · filed 2025-11-05 | $38.99M derived: sum of 2 quarters · filed 2025-11-05 | $38.94M 10-Q · filed 2025-11-05 | $43.76M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $26.27M 10-Q · filed 2025-08-06 | $26.23M 10-Q · filed 2025-08-06 | $31.05M derived: sum of 3 quarters · filed 2026-02-23 | $34.42M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$48.00K 10-Q · filed 2025-05-08 | $4.77M derived: sum of 2 quarters · filed 2026-02-23 | $8.14M derived: sum of 3 quarters · filed 2026-02-23 | $13.51M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.19M derived: sum of 2 quarters · filed 2026-02-23 | $13.56M derived: sum of 3 quarters · filed 2026-02-23 | $13.56M 10-K · filed 2026-02-23 |
| 2023-09-30 | $3.37M 10-Q · filed 2024-11-04 | $8.74M derived: sum of 2 quarters · filed 2024-11-04 | $8.74M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $5.37M 10-Q · filed 2024-08-01 | $5.37M 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |